

Special Issue

Preeclampsia: Pathogenesis, Diagnosis and Treatment

Message from the Guest Editor

Preeclampsia (PE) is a severe pregnancy complication that affects 2–8% of all pregnancies worldwide and accounts for the death of approximately 76,000 women and 500,000 fetuses per year. PE is characterized by new onset hypertension and proteinuria in the second half of pregnancy. The only known cure for PE is the termination of pregnancy, which increases the rate of preterm birth. Pathogenesis of this pregnancy complication has been investigated in many studies. Based on extensive PE research in the past few decades, the old two-stage model has been refined and lately even been extended to six stages. I cordially invite authors and investigators within this complex field of universal interest to submit original research or review articles pertaining to this Special Issue, including studies and opinions on risk factors related to the development of the disease and molecular aspects of its pathogenesis. I would appreciate it if the authors provided a brief section in their manuscript indicating the novelty of their findings or, in the case of review articles, provided personal views on a particular topic.

Guest Editor

Prof. Dr. Joško Osredkar

Clinical Institute of Clinical Chemistry and Biochemistry, University Medical Centre Ljubljana, Zaloška cesta 2, 1000 Ljubljana, Slovenia

Deadline for manuscript submissions

closed (31 July 2020)



Reproductive Medicine

an Open Access Journal
by MDPI

Impact Factor 0.9
CiteScore 1.7



mdpi.com/si/38893

Reproductive Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
reproductivemedicine@mdpi.com

mdpi.com/journal/

reprodmed





Reproductive Medicine

an Open Access Journal
by MDPI

Impact Factor 0.9
CiteScore 1.7



[mdpi.com/journal/
reprodmed](https://mdpi.com/journal/reprodmed)



About the Journal

Message from the Editor-in-Chief

Welcome! Those of you who are interested in reproductive medicine and biology are warmly invited to submit your original research articles, short communications and comprehensive reviews for consideration and publication in *Reproductive Medicine*. Our journal *Reproductive Medicine* is published in open access format, i.e. your articles and reviews are published online immediately after acceptance. The scientific community and the general public will have unlimited and free access to the content as soon as it is published. We would be more than pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Berthold Huppertz

Division of Cell Biology, Histology and Embryology, Gottfried Schatz
Research Center, Medical University of Graz, Graz, Austria

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), Scopus, FSTA, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 20.6 days after submission; acceptance to publication is undertaken in 5.6 days (median values for papers published in this journal in the first half of 2026).